News

COPENHAGEN, Denmark, March 17, 2021— Vipergen ApS today announced the appointment of Leif Kongskov Larsen, Ph.D. as Director of Biology, and the promotion of Allan Beck Christensen, Ph.D., to Director of Screening Technology. Dr. Larsen and Dr. Christensen will report directly to Nils Hansen, Ph.D. Vipergen’s CEO. Dr. Larsen and Dr. Christensen will be members […]

Vipergen Publishes First Technology for ScreeningDNA-Encoded Small-Molecule Libraries (DELs) Inside Living Cells — Vipergen’s Cellular Binder Trap Enrichment® (cBTE) technology provides a robust systemto accelerate and improve drug discovery — — Study published in Journal of the American Chemical Society — COPENHAGEN, Denmark, February 17, 2021— Vipergen ApS announced today a published study describing a

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, December 1, 2020—Casma Therapeutics, Inc. and Vipergen ApS announced today the signing of a drug discovery agreement. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platform to discover novel small-molecule drug leads against a broad range of undisclosed Casma discovery targets. Casma

Copenhagen, Denmark, November 6th, 2020 – – Vipergen ApS announced today the commercial release of the first technology for screening of DNA-encoded small molecule libraries (DELs) inside a living cell. This proprietary technology will significantly accelerate and improve the drug discovery process. Main attributes include, 1) lowering the attrition rate in drug discovery since the

Copenhagen, Denmark, December 20, 2016 Vipergen ApS announced today the signing of a multi-target drug discovery agreement with Merck. Under the terms of the agreement, Vipergen’s small molecule discovery engine, a proprietary high fidelity DNA-encoded library technology platform, will be applied across therapeutic projects to identify novel hits for selected targets from Merck. Merckobtains exclusive

Copenhagen, Denmark, June 22nd,2016–Vipergen ApS announced today the signing of a multi-target drug discovery agreement with Daiichi Sankyo Co., Ltd. (hereinafter “Daiichi Sankyo”). Under the terms of the agreement, Vipergen’ssmall molecule discovery engine, a proprietary high fidelity DNA-encoded library technology platform, will be applied across therapeutic projects to identify novel hits/leads for selected targets from

Copenhagen, Denmark, January 19, 2016 – – Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary secondgeneration DNA-encoded library platform, today announced the initiation of a drug discovery collaboration with Gilead Sciences, Inc. Under the terms of the agreement, Vipergen is applying its small molecule discovery engine, which leverages a

Copenhagen, Denmark, December 21, 2015 – – Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary 2 nd generation DNA-encoded library platform, today announced the initiation of a drug discovery collaboration with Actelion Pharmaceuticals Ltd (a subsidiary of Actelion Ltd, SIX: ATLN), a leading biopharmaceutical company focused on the discovery,

Copenhagen, Denmark, December 18 2015 – – Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary 2nd generation DNA-encoded library platform, today announced the signing of a drug discovery agreement with Amgen Inc., a global leader in the biotech industry. Under the terms of the agreement, Vipergen’s small molecule discovery